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http://djournal homepage: www.elsevier.com/locate/jboEditorialBone Oncology—An emerging multi-disciplinary specialtyThe skeleton and bone marrowmicroenvironment within bone
acts as a critical organ for the development and spread of
metastatic cancer. Bone metastases are common and have major
impact on the physical function and quality of life of cancer
patients. Over the last decade, as our understanding of the
processes involved in metastasis has increased, it has become
clear that bone marrow derived stem cells are intimately involved
in the development of metastases both within and outside bone,
and interactions between cancer and bone cells underpin the
development of skeletal metastases. Additionally, as survival in
many cancers improves, the long-term effects of treatment on
bone health are of increasing importance.
Coupled with the increasing recognition of the biological and
clinical importance of the skeleton in the outcomes for cancer
patients, rapid developments in bone targeted treatments, skele-
tal imaging and bone biomarkers have occurred. The therapeutic
advances, notably bisphosphonates and denosumab, have had a
profoundly positive effect on the care of patients with advanced
malignancy and may have an important role in modifying the
clinical course of certain cancers, especially those arising in the
breast and prostate as well as for patients with multiple mye-
loma. Consequently, bone oncology has emerged as a new
discipline and, in recognition of this, a new journal that brings
together all aspects of the biology and clinical management of
bone disease in cancer patients has been created.
The Journal of Bone Oncology is a peer-reviewed international
journal aimed at presenting basic, translational and clinical high-
quality research related to bone and cancer. As the ﬁrst journal
dedicated to cancer induced bone diseases, we believe it ﬁlls an
important gap in the available literature that adequately
addresses this important research area and are very excited to
have the enthusiastic support of a world class international
editorial board.
The areas covered by the journal include: Pathophysiology, epidemiology, clinical features, prevention
and treatment of bone metastases. Preclinical models of metastasis.
 The bone microenvironment in cancer and the role of stem
cell, bone cell and cancer cell interactions in the development
and spread of malignancy.74/$ - see front matter & 2012 Elsevier GmbH. This is an open access article un
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nThe pharmacology, therapeutic targets, drug development,
clinical trials, side-effects, and health economics of bone
targeted therapy. Causes, prevention and management of cancer treatment
induced bone loss. Preclinical and clinical imaging of the skeleton and develop-
ments in skeletal interventional radiology. Discovery, validation and clinical and translational applica-
tions of bone biomarkers. Radiotherapy and radio-isotopes for the prevention and treat-
ment of bone metastases. Skeletal complications of malignancy including fracture,
hypercalcaemia, and spinal cord compression. Mechanisms and management of bone pain.
 Orthopaedic cancer surgery.
 Primary malignant bone tumours.
 Clinical guidelines of relevance to bone health in oncology.
 Multidisciplinary patient care.
We are delighted, in partnership with Elsevier, to bring you
this ﬁrst issue of the Journal of Bone Oncology. Initially, 4 issues a
year will be published and be made available via Science Direct.
Our vision is to provide a journal to scientists and clinicians that
bridges oncology and bone biology and is of broad appeal to all
involved in cancer research and treatment. We do hope you will
want to help make this journal a success by submitting relevant
original research articles, review articles, editorials, case reports
and opinion pieces.Robert Coleman n
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